Cancer Supportive Care Drugs Market Analysis Report By Therapeutic Class (G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs, ESAs), By Major Markets, Vendor Landscape, And Segment Forecasts, 2016 - 2022

Cancer Supportive Care Drugs Market Analysis Report By Therapeutic Class (G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs, ESAs), By Major Markets, Vendor Landscape, And Segment Forecasts, 2016 - 2022

The global cancer supportive care drugs market size is expected to be valued at USD 23.5 billion by 2022, as per a new report by Grand View Research, Inc., progressing at a CAGR of 1.8% during the forecast period. The market is anticipated to be driven by large number of side-effects associated with cancer treatment, increasing uptake of biosimilars, rising expenditure on healthcare, and availability of effective treatment methods, including target specific and tailored treatments.

Chemotherapy and radiotherapy are traditional methods for cancer treatment with approximately four million people receiving chemotherapy every year. Supportive care products are essential to prevent and manage symptoms and side-effects of cancer and its treatment.Among major cancer types, lung and breast cancers are the most prominent cancer type with the highest demand for supportive care drugs.

G-CSFs and ESAs therapeutic classes are witnessing a fundamental shift from biologics to biosimilars. The market for cancer pain, chemotherapy induced nausea and vomiting, and cancer induced bone diseases will grow significantly during the forecast period, due to new product launches and high unmet needs. The cancer pain market is estimated to witness a shift from opioids to non-opioids therapies. The shift will be backed by patent loss, high mortality, addiction, and major safety issues associated with narcotic agents.

Further key findings from the report suggest:

  • Some of the key players operating in this industry are Amgen, Johnson & Johnson, Merck, Roche, Helsinn Healthcare, Heron Pharma, and Tesaro
  • Among EU5, Germany captured the second position in the global cancer support care drugs market. Japan is poised to witness the fastest growth over the forecast period
  • The CINV drugs market will be propelled by widening base of patients, increasing adoption of chemotherapeutic drugs, and launch of new drug delivery approaches to improve patient compliance
  • In Europe, Zarzio has taken over its reference product Neupogen in terms of market share
  • Late stage pipeline products include non-opioids such as Tanezumab and HTX-011
  • Newer immunotherapies directed against PD-1 ligands and PD-L1 proteins have shown to be more effective with a superior safety profile


Chapter 1 Research Methodology
1.1. Information procurement
1.2. Information or Data Analysis
1.2.1. Market Formulation & Validation
Chapter 2 Executive Summary
Chapter 3 Disease Primer and Epidemiology
3.1. Disease Primer
3.1.1. Current Prevalence Rate and Incidence Rate for Seven Major Markets (U.S., Japan, EU5)
Chapter 4 Global Cancer supportive care drugs market Overview
4.1. Major Therapeutic Classes for Cancer Supportive Care
4.2. Market, by Therapeutic Class
4.3. Market Size and Forecast (2016 - 2022)
4.4. Market Size and Forecast, by Seven Major Markets (2016 - 2022)
4.4.1 U.S. Sales by Therapeutic Class (2016 - 2022)
4.4.2 U.K. Sales by Therapeutic Class (2016 - 2022)
4.4.3 Germany Sales by Therapeutic Class (2016 - 2022)
4.4.4 France Sales by Therapeutic Class (2016 - 2022)
4.4.5 Italy Sales by Therapeutic Class (2016 - 2022)
4.4.6 Spain Sales by Therapeutic Class (2016 - 2022)
4.4.7 Japan Sales by Therapeutic Class (2016 - 2022)
4.5. Market Share Distribution, by Company (2016 - 2022)
4.6. Sales Performance, by Drug Class (2016 - 2022)
4.6.1. Granulocyte Colony Stimulating Factors - Chemotherapy Induced Neutropenia (CIN)
4.6.2. Erythropoietin Stimulating Agents (ESAs) for Chemotherapy Induced Anemia (CIA)
4.6.3. Anti-emetics for Chemotherapy Induced Nausea and Vomiting (CINV)
4.6.4. Bisphosphonates for Cancer Induced Bone Diseases
4.6.5. Opioids and NSAIDs for Cancer Pain
4.7. Market Dynamics and Brand Strategies
4.8. Patent Expiry Analysis
4.9. Cancer supportive care drugs market: Drivers and Restraints
4.9.1. Market Drivers
4.9.2. Market Challenges
4.10. M&A, Deal Landscape (2013-2017 YTD)
4.10.1. Mergers & Acquisitions
4.10.2. Deals Landscape
4.11. Evolution of Biosimilars
4.12. Emerging Markets
4.13. Pricing and Reimbursement Scenario
4.14. Cancer Supportive Care Sector SWOT
Chapter 5 Global Cancer Supportive Care Pipeline Intelligence
5.1. Pipeline Landscape
5.2. Leading Drugs in Development
5.3. Key R&D Trends
5.4. Pipeline Landscape
5.4.1. Late Stage Pipeline Drugs
5.5. Profiles of Disruptive Drugs
5.6. Global Pipeline Forecast
Chapter 6 Company Profiles
6.1. Amgen
6.1.1. Company Overview
6.1.2. Current Product Portfolio
6.1.3. Product Forecast Sales through 2022
6.1.4. Strategic Initiatives
6.1.4.1. Key Company News Flow
6.1.5. Pipeline Analysis and Overview
6.1.6. SWOT
6.2. Merck
6.2.1. Company Overview
6.2.2. Current Product Portfolio
6.2.3. Product Forecast Sales through 2022
6.2.4. Strategic Initiatives
6.2.4.1. Key Company News Flow
6.2.5. SWOT
6.3. Helsinn Healthcare
6.3.1. Company Overview
6.3.2. Current Product Portfolio
6.3.3. Product Forecast Sales through 2022
6.3.4. Strategic Initiatives
6.3.4.1. Key Company News Flow
6.3.5. Pipeline Analysis and Overview
6.3.6. SWOT
6.4. Johnson & Johnson
6.4.1. Company Overview
6.4.2. Current Product Portfolio
6.4.3. Product Forecast Sales through 2022
6.4.4. Strategic Initiatives
6.4.4.1. Key Company News Flow
6.4.5. SWOT
6.5. Heron Pharma
6.5.1. Company Overview
6.5.2. Current Product Portfolio
6.5.3. Product Forecast Sales through 2022
6.5.4. Strategic Initiatives
6.5.4.1. Key Company News Flow
6.5.5. Pipeline Analysis and Overview
6.5.6. SWOT
6.6. Roche
6.6.1. Company Overview
6.6.2. Current Product Portfolio
6.6.3. Product Forecast Sales through 2022
6.6.4. Strategic Initiatives
6.6.4.1. Key Company News Flow
6.6.5. SWOT
6.7. Novartis (Sandoz)
6.7.1. Company Overview
6.7.2. Current Product Portfolio
6.7.3. Product Forecast Sales through 2022
6.7.4. Strategic Initiatives
6.7.4.1. Key Company News Flow
6.7.5. Pipeline Analysis and Overview
6.7.6. SWOT
6.8 Tesaro
6.8.1. Company Overview
6.8.2. Product Portfolio
6.8.3. Product Forecast Sales through 2022
6.8.4. Strategic Initiatives
6.8.4.1. Key Company News Flow
6.8.5. SWOT
Chapter 7 Market Outlook
7.1. What the Future Holds
7.2. The Winners and Losers
7.3. Emerging Companies/New Technology Platforms
7.4. The Road Ahead
List of Tables
TABLE 1 Normal vs Cancer Cells
TABLE 2 Anti-emetics - Major Products for CINV
TABLE 3 Erythropoietin Stimulating Proteins Drug Class - Major Products for CIA
TABLE 4 G-CSFs Drug Class - Major Products for Neutropenia
TABLE 5 Opioids and NSAIDs Drug Class - Major Products for Cancer Pain
TABLE 6 Bisphosphonates Drug Class for Cancer Induced Bone Diseases
TABLE 7 Cancer Incidence and Deaths in Seven Major Markets
TABLE 8 Cancer Incidence in the U.S.
TABLE 9 Cancer Cases in the U.S.
TABLE 10 Most Prevalent Cancers in Europe
TABLE 11 Cancer Incidence in the U.K.
TABLE 12 Cancer Cases in Germany
TABLE 13 Cancer Incidence in Germany
TABLE 14 Cancer Incidence in France
TABLE 15 Cancer Incidence in Spain
TABLE 16 Age and Gender Specific Incidence and Mortality Cancer Cases in Italy
TABLE 17 Cancer Incidence in Italy
TABLE 18 Cancer Incidence in Japan
TABLE 19 Cancer supportive care drugs market - Therapeutic Class
TABLE 20 Sales Performance, by Therapeutic Class
TABLE 21 Market Share, by Indication
TABLE 22 U.S. Sales by Drug Class (2016 - 2022)
TABLE 23 U.K Sales by Drug Class (2016 - 2022)
TABLE 24 Germany Sales by Drug Class (2016 - 2022)
TABLE 25 France Sales by Drug Class (2016 - 2022)
TABLE 26 Italy Sales by Drug Class (2016 - 2022)
TABLE 27 Spain by Drug Class (2016 - 2022)
TABLE 28 Japan Sales by Drug Class (2016 - 2022)
TABLE 29 G-CSF Drug Class, Sales (2016 - 2022)
TABLE 30 ESAs Drug Class, Sales (2016 - 2022)
TABLE 31 Antiemetics Drug Class for CINV Sales (2016 - 2022)
TABLE 32 Bisphosphonates Drug Class Sales (2016 - 2022)
TABLE 33 Opioids and NSAIDs for Cancer Pain Sales (2016 - 2022)
TABLE 34 Patents Expiry Analysis for Drugs in Cancer Supportive Care
TABLE 35 Most Prevalent Cancers Using Chemotherapy and/or Radiation Therapy as a Treatment Option in the U.S. (2016)
TABLE 36 Biosimilars of Erythropoietin Stimulating Proteins (Epogen/Procrit)
TABLE 37 Biosimilars of Erythropoietin Stimulating Proteins (Aranesp)
TABLE 38 Biosimilars of Neupogen (filgrastim) for Treatment of CIN
TABLE 39 Biosimilars of Neulasta (Pegfilgrastim) for treatment of CIN
TABLE 40 R&D Pipeline Overview - Leading Drugs
TABLE 41 Late Stage Pipeline
TABLE 42 Tanezumab
TABLE 43 Rolontis
TABLE 44 NEPA IV (fosnetupitant and palonosetron fixed combination)
TABLE 45 Anamorelin
TABLE 46 HTX-011
TABLE 47 Myelo001
TABLE 48 Pipeline Forecast
TABLE 49 Amgen- Product Forecast Sales (2016 - 2022)
TABLE 50 Merck- Product Forecast Sales (2016 - 2022)
TABLE 51 Helsinn Product Forecast Sales (2016 - 2022)
TABLE 52 Johnson & Johnson Product Forecast Sales (2016 - 2022)
TABLE 53 Heron Pharma Product Forecast Sales (2016 - 2022)
TABLE 54 Roche Product Forecast Sales, (2016 - 2022)
TABLE 55 Novartis Product Forecast Sales (2016 - 2022)
TABLE 56 Tesaro Product Forecast Sales (2016 - 2022)
List of Figures
FIG. 1 Market research process
FIG. 2 Information Procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain based sizing & forecasting
FIG. 6 QFD modelling for market share assessment
FIG. 7 Age Specific Cancer Incidence in Japan (2010 - 2012)
FIG. 8 Market Shares, by Indication (2016 - 2022)
FIG. 9 Market, by Seven Major Markets, 2016 - 2022
FIG. 10 Market Shares Distribution, by Company (2016 - 2022)
FIG. 11 G - CSFs, Market Shares (2016 - 2022)
FIG. 12 ESAs, Market Shares (2016 - 2022)
FIG. 13 ESAs - Market Shares Distribution, 2016 - 2022
FIG. 14 Anti - emetics, Market Shares Distribution, 2016 - 2022
FIG. 15 Bisphosphonates, Market Share Distribution, 2016 - 2022
FIG. 16 Cancer Pain Drugs, Market Share Distribution, 2016 - 2022
FIG. 17 Cost Difference between Reference Product (filgrastim) and Biosimilars in Europe
FIG. 18 Radiotherapy - Cost - Japan vs U.K. vs Germany
FIG. 19 Cancer Supportive Care Sector SWOT
FIG. 20 Amgen SWOT Analysis
FIG. 21 Merck SWOT Analysis
FIG. 22 Helsinn Healthcare SWOT Analysis
FIG. 23 Johnson & Johnson SWOT Analysis
FIG. 24 Heron Pharma SWOT Analysis
FIG. 25 Roche SWOT Analysis
FIG. 26 Novartis SWOT Analysis
FIG. 27 Tesaro SWOT Analysis

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook